Hydroxylamines and derivatives for the inhibition of complement activation

a technology of hydroxylamines and derivatives, applied in the field of immunopharmacology, can solve the problems of peptides causing damage through their effect on neutrophils and mast cells, damage to endogenous cells, and damage to endogenous cells, and achieve the effects of inhibiting complement activation, inhibiting complement activation, and inhibiting drusen formation

Inactive Publication Date: 2007-08-30
COLBY PHARMA CO
View PDF32 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In certain situations, the complement system can produce deleterious effects.
For example, inappropriate activation of complement may result in damage to endogenous cells.
These peptides induce damage through their effects on neutrophils and mast cells.
To date, there are no clinically viable inhibitors of complement activation although certain candidates for clinical use exist.
However, each substance possesses the disadvantage of being large molecular weight proteins (240 kDa and 26,000 kDa, respectively) that are difficult to manufacture and must be administered by infusion.
However, hydroxylamines heretofore have not been reported as possessing any efficacy to inhibit complement activation, or to treat complement- or drusen-mediated pathologies such as AMD.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hydroxylamines and derivatives for the inhibition of complement activation
  • Hydroxylamines and derivatives for the inhibition of complement activation
  • Hydroxylamines and derivatives for the inhibition of complement activation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] Various terms relating to the methods and other aspects of the present invention are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition provided herein.

[0021] The following abbreviations may be used in the specification and examples: AMD, age-related macular degeneration; MAC, membrane attack complex.

[0022] The terms “treating” or “treatment” refer to any success or indicia of success in the attenuation or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement, remission, diminishing of symptoms or making the injury, pathology, or condition more tolerable to the patient, slowing in the rate of degeneration or decline, making the final point of degeneration less debilitating, improving a subject's physical or mental well-being, or prolon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
water/n-octanol partition coefficientaaaaaaaaaa
Login to view more

Abstract

Methods for the inhibition of complement activation, for the treatment of complement-mediated pathologies, and for the treatment of drusen-mediated pathologies are disclosed. The methods utilize hydroxylamine compounds and ester derivatives thereof, administered to subjects in effective amounts.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application claims priority to U.S. Provisional Application Ser. No. 60 / 775,478, filed Feb. 22, 2006, the disclosure of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The invention relates generally to the field of immunopharmacology. Specifically, the invention features compositions and methods utilizing hydroxylamines and certain ester derivatives for inhibiting the activation of the complement cascade and for treating pathologies that result from complement activation. BACKGROUND OF THE INVENTION [0003] Various patents and other publications are referenced herein. The contents of each of these patents and publications are incorporated by reference herein, in their entireties. The entire contents of commonly-owned co-pending U.S. Publication Nos. 2004 / 0002461, 2005 / 0130906 and 2005 / 0131025 are incorporated by reference herein. [0004] The complement system is an important weapon in the body'...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/445A61K31/421
CPCA61K31/445A61K31/421
Inventor PATIL, GHANSHYAMMATIER, WILLIAM L.
Owner COLBY PHARMA CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap